Deutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Deutsche Bank AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 149,240 shares of the biotechnology company's stock, valued at approximately $12,165,000. Deutsche Bank AG owned 0.11% of Arrowhead Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of ARWR. Royal Bank of Canada boosted its position in shares of Arrowhead Pharmaceuticals by 30.2% during the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company's stock worth $576,000 after purchasing an additional 10,496 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at about $514,000. Goldman Sachs Group Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock valued at $22,189,000 after purchasing an additional 447,456 shares during the period. Empowered Funds LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares during the period. Finally, Focus Partners Wealth boosted its holdings in Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after buying an additional 15,123 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARWR has been the topic of several recent analyst reports. Leerink Partners upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a "market perform" rating in a research report on Wednesday, June 17th. Sanford C. Bernstein lifted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a "market perform" rating in a research report on Wednesday, May 13th. Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a "buy" rating in a research note on Wednesday, July 22nd. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 27th. Finally, Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a "buy" rating and a $98.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $97.33.

Arrowhead Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ ARWR opened at $87.11 on Friday. The firm's 50-day moving average is $82.84 and its two-hundred day moving average is $72.87. The company has a market capitalization of $12.27 billion, a PE ratio of -38.72 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.44 and a 12-month high of $95.49. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analysts' expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company's revenue for the quarter was up 171.0% on a year-over-year basis. During the same period last year, the business earned ($1.26) earnings per share. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares of the company's stock, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source